Feeds

Friends and families deal with drug trial fallout

Victims 'screamed'

Providing a secure and efficient Helpdesk

Details continue to emerge of the London drug test that put six volunteers in a critical condition.

Speaking to the Mirror, Dolores Flanagan, aunt of 21-year-old Ryan Wilson, one of the men that reacted badly to the drug, said: "The family are in pieces. He's in the hands of God now."

The Sun got hold of one of the more fortunate participants in the trial, who seems to have been given a placebo. Raste Khan said: "Some screamed out that their heads felt like they were going to explode."

Late this afternoon, authorities at Northwick Park Hospital in London said the condition of four of the men is showing signs of improvement. A statement said: "The other two men remain critical and it could be a while until they show significant change."

Student David O'Donnell, 19, was due to take part in the next stage of testing of the drug in April at a higher dose. A friend of his took part in the trial and is seriously ill. O'Donnel told the BBC: "I am very worried about him indeed, but I had a message from my friends to say they have managed to get in contact with him."

The distressed girlfriend of one of the men said yesterday that he looked like "the Elephant Man". Northwick Park intensive care clinical director Ganesh Suntharalingam tried to calm fears: "These patients sometimes need a lot of fluid, and one result of that is severe but temporary swelling. This is distressing for relatives to see, but it does go away on recovery and it has no long-term effects."

The experimental drug TGN1412 administered to the six was aimed at combatting immunological diseases - chronic conditions like rheumatoid arthritis, multiple sclerosis and leukaemia. German firm Tegenero had contracted American firm Parexel to carry out the first human trials for the new therapy in Britain.

TGN1412 is designed to target rogue T-cells which cause these illnesses. In the trial it triggered a massive inflammatory response in the healthy human volunteers, despite passing animal testing without problems.

TeGenero says it has apologised to the sick men's families.

A TeGenero statement says: "The drug was developed in accordance with all regulatory and clinical guidelines and standards."

Parexel works as a contractor running testing of many new drugs. It agreed that all guidelines had been followed. Its testing programmes draw in cash-strapped students with offers of easy money. Parexel's website trumpets: "Paid time to yourself."

It's unclear if there will be any kind of compensation pay out.

In an open letter to the British Medical Journal back in February, University of London Professor Desmond Laurence criticised the unclear arrangements for compensation when drug trials go wrong.

He said documents covering drug trials were not written in plain language and therefore did not meet the legal requirement of fairness and openness under consumer law. He observed: "The cost of compensation for non-negligent harm falls upon the injured patients themselves."®

Internet Security Threat Report 2014

More from The Register

next story
MARS NEEDS WOMEN, claims NASA pseudo 'naut: They eat less
'Some might find this idea offensive' boffin admits
SECRET U.S. 'SPACE WARPLANE' set to return from SPY MISSION
Robot minishuttle X-37B returns after almost 2 years in orbit
LOHAN crash lands on CNN
Overflies Die Welt en route to lively US news vid
Experts brand LOHAN's squeaky-clean box
Phytosanitary treatment renders Vulture 2 crate fit for export
No sail: NASA spikes Sunjammer
'Solar sail' demonstrator project binned
America's super-secret X-37B plane returns to Earth after nearly TWO YEARS aloft
674 days in space for US Air Force's mystery orbital vehicle
Carry On Cosmonaut: Willful Child is a poor taste Star Trek parody
Cringeworthy, crude and crass jokes abound in Steven Erikson’s sci-fi debut
Origins of SEXUAL INTERCOURSE fished out of SCOTTISH LAKE
Fossil find proves it first happened 385 million years ago
Human spacecraft dodge COMET CHUNKS pelting off Mars
Odyssey orbiter yet to report, though - comet's trailing trash poses new threat
prev story

Whitepapers

Forging a new future with identity relationship management
Learn about ForgeRock's next generation IRM platform and how it is designed to empower CEOS's and enterprises to engage with consumers.
Why and how to choose the right cloud vendor
The benefits of cloud-based storage in your processes. Eliminate onsite, disk-based backup and archiving in favor of cloud-based data protection.
Three 1TB solid state scorchers up for grabs
Big SSDs can be expensive but think big and think free because you could be the lucky winner of one of three 1TB Samsung SSD 840 EVO drives that we’re giving away worth over £300 apiece.
Reg Reader Research: SaaS based Email and Office Productivity Tools
Read this Reg reader report which provides advice and guidance for SMBs towards the use of SaaS based email and Office productivity tools.
Security for virtualized datacentres
Legacy security solutions are inefficient due to the architectural differences between physical and virtual environments.